Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve activity study aims to unlock stomach disorder secrets

NCT ID NCT03896126

Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study measured vagal nerve activity after eating in 43 people with gastroparesis (a stomach disorder) and healthy volunteers. The goal was to establish normal and abnormal nerve function patterns. The study used an FDA-approved device to track heart-based nerve signals. Results may help design future treatments using nerve stimulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help define what normal and abnormal vagal tone looks like, potentially guiding future vagal nerve stimulation treatments for gastroparesis.
What could go wrong
This is a small, early observational study that was terminated, so results may be limited. It does not test any treatment directly, and findings may not lead to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Jan 2019

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

60 Patients (20 Gastroparesis and 40 Controls) between the ages of 20-49.

Ages

20 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Male or female. 2. Age 20-49 years old. 3. Healthy volunteer or established diagnosis of idiopathic gastroparesis as per AGA (American Gastroenterology Association) guidelines. 4. Participant is capable of giving informed consent. 5. Gastroparesis patients must be on stable doses of medications for gastroparesis for preceding 4 weeks prior to enrollment (including cholinergics, anti-cholinergics, dopamine and serotonin receptor agonists/antagonists, motility agents, neuromodulators, herbals). Exclusion criteria. 1. Diagnosis of systemic autonomic nerve dysfunction (i.e. POTS, CAN). 2. Surgical-related gastroparesis 3. Extrinsic myopathy or neuropathy causing gastroparesis. 4. Use of narcotic pain medications in the preceding 2 weeks of study enrollment. 5. Patients with enteric feeding tubes or requiring parenteral nutrition. 6. Patients with severe disease flare requiring hospitalization or frequent emergency room visits (last within 3 months or less of enrollment). 7. Untreated significant depression or suicidal thoughts. 8. Pregnant or breast-feeding women. 9. History of gastric pacemaker implantation. 10. Patients with prior gastric surgery, including fundoplication, partial/total gastrectomy, pyloroplasty, or gastric bypass. 11. Patients with implantable electronic devices. 12. Dairy, wheat, or egg allergy/intolerance. 13. Allergy to commercial clinical adhesive for EKG stickers. 14. Non-English speaker and/or hearing impaired (as participants need to follow English verbal commands and cues for the experiment).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroparesis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroparesis idiopathic gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroparesis

Contacts and locations

Locations

  • Stanford University Medical Center

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.